益普索健康服务报告2025：一项覆盖30个国家的益普索全球顾问调查

A 30-Country IpsosGlobal Advisor SurveyOctober 2025 Introduction Welcome to the seventh edition of theIpsos Health Service Report. Since2018 we have been tracking people’sattitudes and perceptions on theirhealthcare system and its biggestproblems. They are now being talked of as justanother part of the weight loss toolkit.In much the same way you would go tothe gym. information on healthcare bythemselves, rather than just relying onwhat their doctor tells them. Nowhere within health is thispoliticisation more apparent than invaccines. Misinformation aroundvaccinationsis being spread by some ofthe most influential voices around theworld. We see falling support in manycountries for compulsory vaccines forinfectious diseases. The online narrative is not being drivenby the pharma industry or traditionalhealthcare providers, but shaped byonline voices. In this issue we look at GLP-1s includingawareness around the world andwhether people think it will have animpact on obesity levels. Understanding perceptions, or perhapsmisperceptions, around healthcare hasnever been more important. Health, likemany aspects of society, is becomingmore politicised and coupled with thisthe traditional sources of knowledge,such as doctors andthepharma sector,have less influence. People are most likely to say they hearof GLP-1 drugs, which go by brandnames like Ozempic orMounjaro,through social media. We explore thesocial media conversations aroundGLP-1s and how the drugs, which areonly available via prescription, arebeing used and marketed as a way for“healthy” people to keep the weight off. Wehope you find this report useful. Ifyou have any questions about what’scovered here for your country, categoryor industry, please get in touch. Jamie Stinson, Content Director, IpsosJamie.Stinson@Ipsos.com In ourIpsos Global Trends worktwo-thirds say they always try and find out At a glance Perceived biggesthealthcare problems: 45% on average across 30countries say mental healthis the biggest healthconcern. This is up from27% in 2018. Cancer,stress,obesity, and drug abusefollow as concerns. across 30 countries haveheard of GLP-1 drugs, suchas Ozempic,Wegovy,Zepbound,RybelsusorMounjaro. Awareness ishighest in the US (74%). 43% 28% rate the quality ofhealthcare they receive asgood. This ranges from75% in Malaysia feelingtheir healthcare is good, toonly 12% in Hungary. on average think the quality oftheir healthcare will improve overthe coming years, down from 34%in 2018. Twenty-one per centthink the quality will get worse. Summary Mental health is seen as the top healthproblem Low awareness of GLP-1s globally, buthigh in the most advanced economies People much more likely to think thelevel of care they get is good vs. bad Across 30 countries only 36% have heardabout GLP-1 drugs such as Ozempic andWegovy. However, this rises to 74% in the US.Despite much discussion about theeffectiveness of the drugs, only around one ineight think there will be fewer obese people intheir country in 10 years’ time. Four in ten (43%) rate the quality of thehealthcare they have access to in theircountry as good. Only 22% rate the care theyreceive as poor. 45% on average across 30 countries seemental health as a problem in their nation. Itranks ahead of cancer (41%) and obesity (25%)as the biggest health problems. Perception ofmental health as an issue rose rapidly duringthe pandemic and the proportion that see it asa problem has increased by 18 points since2018. Malaysia and the Netherlands are the mostlikely to feel their healthcare system is good.Britain and Canada have experienced markedfalls in their ratings in recent years. Of those that have heard of the drugs aremost likely to have been made aware of themonline. 45% heard about GLP-1s from socialmedia, while only 19% knew about them froma medical professional. As worry about mental health has risen, worryabout stress has risen too. 31% see it as aproblem. At the same time 59% say in the pastyear there have been points when they were sostressed they could not cope. While many European countries are morelikely to rate their healthcare as good ratherthan poor, many think it will get worse in thefuture. We explore how the new narrative aroundGLP-1s is not being set by pharma companiesor traditional healthcare companies, butinfluencers and telehealth. One in two (51%) in France, 39% in Germanyand 35% in the Netherlands expect quality togo down in the coming years. 76%alsosay mental and physical health areequally important, but just 38% think theirhealthcare system treat them as such. CONTENTS 4 1 3 2 The biggest healthproblems Obesity and GLP-1s Healthcare systemsatisfaction andchallenges Mental health 7 5 6 Detailed resultsand countrybreakdowns Methodology Vaccines and trust PART ONE:HEALTHCARE IN 2025 Obesity and GLP-1s From medical to lifestyle on average across 30countries have heard ofGLP-1 drugs and theirbrand names.36% drugs are high and currently they